Solitary Fibrous Tumor (SFT)

A solitary fibrous tumor (SFT) is a rare growth that starts from the body’s connective tissue (the “fibrous” framework that supports organs).
It can grow in almost any location. It was first found in the lining of the lung (the pleura), but doctors now see it in the chest, abdomen, pelvis, head and neck, the limbs, and even the covering of the brain and spinal cord (the meninges). SFT is usually slow growing. Many tumors are benign (not cancer). Some behave more aggressively. A small group can become malignant (cancerous), spread, or come back after treatment. NCBI

A solitary fibrous tumor is a rare growth that starts from fibroblastic (connective-tissue) cells and can appear almost anywhere in the body. It used to be known mainly as a pleural (chest lining) tumor, but we now know it can occur in the chest, abdomen, pelvis, limbs, head and neck, brain coverings (meninges), and many other sites. Under the microscope, it often shows a “patternless” weave of spindle cells with many small, branching (“staghorn”) blood vessels. A hallmark lab finding is strong nuclear staining for STAT6 on immunohistochemistry, which points to an underlying NAB2-STAT6 gene fusion—a driver change seen in most SFTs. This marker helps doctors distinguish SFT from other look-alike tumors. NaturePMCPubMed

SFTs usually grow slowly, but a meaningful minority behave aggressively—recurring locally or spreading (metastasizing) to places like the lungs, liver, bone, or other soft tissues. Doctors estimate the lifetime metastatic risk using a validated risk model (Demicco) that combines age, tumor size, mitotic rate, and necrosis to classify tumors into low, intermediate, or high risk of metastasis. This model is widely used in clinics and research today. NaturePubMed

Doctors now know a key molecular “signature” of SFT. Almost all SFTs carry a specific gene change called the NAB2–STAT6 fusion. This fusion moves the STAT6 protein into the nucleus (the cell’s control center). In routine testing, that shows up as strong nuclear STAT6 staining on immunohistochemistry. This finding is very helpful because it “marks” SFT and separates it from look-alike tumors. PMCScienceDirectNCBI

A small number of SFTs make too much of a growth factor called IGF-2. This can cause serious, repeated low blood sugar (hypoglycemia). This special situation is called Doege–Potter syndrome. When doctors remove the tumor, the low sugar problem usually resolves. PubMedOxford AcademicPMC

SFT is rare. It can occur at any age but is most often found in adults in mid-life or later. Men and women are both affected. The risk of spread (metastasis) or recurrence varies. Doctors estimate that a minority of SFTs will behave aggressively over time. To help predict behavior, specialists use clinical-pathologic risk tools (for example, the Demicco risk model). These tools consider age, tumor size, and mitotic activity (how fast cells are dividing), and in an updated version, tumor necrosis. Higher scores mean higher risk. Modern PathologyPubMedPMC

---

Types of solitary fibrous tumor

Doctors use “types” to describe patterns they see under the microscope, in scans, and in the clinic. These are not different diseases; they are faces of the same tumor family.

1. Classic (conventional) SFT.
   The most common pattern. Cells are spindle-shaped and arranged around many small, branching blood vessels. Growth is often well circumscribed.

2. Cellular SFT.
   More crowded (hypercellular) under the microscope. Sometimes behaves more actively than classic SFT.

3. Malignant SFT.
   Shows high cellularity, many mitoses (cells dividing), cellular atypia (cells look abnormal), necrosis (dead tissue), and infiltrative borders. This group has a higher risk of recurrence and spread.

4. Dedifferentiated SFT.
   A portion of the tumor abruptly changes into a high-grade, different-looking sarcoma. This is rare but more aggressive.

5. Fat-forming (lipomatous) SFT.
   Contains mature fat mixed with the classic SFT pattern.

6. Giant cell-rich SFT (formerly “giant cell angiofibroma”).
   Has many giant cells and a more cellular appearance, often in the head and neck or orbit.

7. Pleural (thoracic) SFT.
   Arises from the pleura in the chest. May cause cough, chest pain, shortness of breath, or be found by chance on imaging. NCBI

8. Extrapleural SFT.
   Occurs outside the pleura—abdomen, pelvis, retroperitoneum, limbs, head and neck, or skin.

9. Meningeal SFT (formerly grouped with hemangiopericytoma).
   In the brain or spinal coverings. The 2021 WHO CNS classification recognizes SFT/HPC as a spectrum with grades. Higher grade lesions act more aggressively. thejns.org

10. Orbital SFT.
    In the eye socket. Usually benign and slow. Complete surgical removal is the main treatment. NCBI

(Clinicians may also describe tumors by risk level using models such as Demicco or its modified versions that add necrosis, because this helps guide follow-up intensity. PubMedPMC)

---

Causes” and mechanisms

The true cause of SFT in most people is unknown. There is no proven lifestyle, diet, or infection cause. However, we do understand key mechanisms that drive the tumor. It is most honest to explain them in simple terms:

1. NAB2–STAT6 gene fusion is the central driver. Two genes join abnormally and create a fusion protein that changes how cells regulate growth. This is found in most SFTs. PMCBioMed Central

2. Nuclear STAT6 protein (caused by the fusion) turns on growth programs in the cell’s nucleus. This is why STAT6 staining is a hallmark test. PMC

3. EGR1 pathway activation. The fusion can activate EGR1-dependent genes, which support cell growth and survival. BioMed Central

4. Angiogenesis (new blood vessel growth). SFTs have many branching vessels; pro-angiogenic signals like VEGF help them grow.

5. IGF-2 overproduction in some tumors leads to Doege–Potter syndrome with low blood sugar. The tumor releases “big” IGF-2 that mimics insulin. PubMedOxford Academic

6. TERT promoter mutations are reported in some malignant SFTs and may relate to aggressive behavior (research area). PMC

7. TP53 and other tumor suppressor pathway changes can appear in higher-grade or dedifferentiated SFT (research area). PMC

8. Epigenetic changes (methylation patterns) can shape tumor behavior (under study). PMC

9. Tumor microenvironment (support cells, blood supply, immune cells) may support growth (research area). Nature

10. Different NAB2–STAT6 fusion variants exist. Some variants correlate with where the tumor grows and how it behaves, but this is a nuanced area and still being studied. ScienceDirect

The rest of the “causes” often listed online (like trauma, prior surgery, or simple irritation) are not proven causes of SFT. If you see long “exposure” lists, read them with caution.

For completeness—and to meet a long “causes” list request—here are additional context factors doctors sometimes discuss. These are associations or research signals, not proven everyday causes:

11. Cellular aging (SFT is more common with age; aging cells collect mutations). Modern Pathology

12. Genomic instability in a subset of aggressive SFTs. PMC

13. High mitotic activity as a marker of aggressive biology rather than a cause. PubMed

14. Tumor necrosis as a sign of an outgrowing blood supply and more aggressive behavior (again, a marker). PMC

15. Hypercellularity and hemorrhage are morphologic risk features used in some scoring systems, but they are not root causes. JTO

16. CNS location with higher grade features tends to behave more aggressively due to site and grade. thejns.org

17. Large size increases risk of future spread (again, a risk feature rather than a cause). Modern Pathology

18. Variant gene fusions may link to site/behavior patterns (research). ScienceDirect

19. Angiogenic signaling balance (VEGF/PDGFR pathways) supporting the rich blood supply (research). Nature

20. Immune environment differences that may influence growth or response (research). Nature

The key take-home: NAB2–STAT6 fusion is the central, proven driver. Many other items above are risk features or research leads, not day-to-day “causes.”

---

Common symptoms

Symptoms depend on where the tumor grows and how big it gets. Many SFTs cause no symptoms at first and are found by chance on imaging.

1. A painless lump or swelling that you can feel, especially in the limb, trunk, head/neck, or groin. It may grow slowly.

2. Fullness or pressure in the chest or abdomen, if the tumor is inside those spaces.

3. Chest pain or shortness of breath for pleural (thoracic) SFTs. The tumor can press on the lung. NCBI

4. Cough that does not go away if a chest tumor irritates the airways. NCBI

5. Abdominal pain, bloating, constipation, or early fullness after small meals if the tumor is in the abdomen or pelvis.

6. Changes in urination or pelvic pressure if the tumor presses on the bladder or pelvic nerves.

7. Neck mass, hoarseness, swallowing trouble, or a feeling of throat fullness with head and neck tumors.

8. Eye symptoms like bulging of one eye (proptosis), double vision, or eye pain with orbital SFT. NCBI

9. Numbness, tingling, or weakness if the tumor compresses a nerve or the spinal cord.

10. Back pain or radicular pain if near the spine or nerves.

11. Headaches or seizures if meningeal SFT affects the brain coverings. thejns.org

12. Unplanned weight loss or fatigue in more aggressive cases.

13. Night sweats or low-grade fevers (less common; non-specific).

14. Low blood sugar symptoms—sweating, confusion, fainting—when the tumor makes too much IGF-2 (Doege–Potter syndrome). These episodes can be severe and repeat. PubMed

15. Symptoms after incomplete surgery—a mass that seems to return or grow again in the same place.

---

How doctors diagnose SFT

Diagnosis is a step-by-step process. It includes a careful history, a full physical exam, imaging, and tissue testing. Below are 20 diagnostic tests, grouped for clarity. Not all patients need every test. Doctors choose based on tumor size, site, and symptoms.

A) Physical exam

1. General inspection and palpation of the mass.
   The doctor looks and feels for size, depth (above or below the fascia), mobility, tenderness, warmth, and skin changes. A soft, movable, painless mass suggests a slow process, but features alone cannot prove SFT. Size matters for risk tools. Modern Pathology

2. Regional lymph node check.
   SFT usually spreads to lungs or liver rather than lymph nodes, but nodes are checked as part of a full exam.

3. Chest and breathing exam.
   Listening for reduced breath sounds if there is a large pleural tumor. NCBI

4. Neurologic screen.
   Simple strength, sensation, reflexes, and cranial nerve checks if the mass is near nerves, the spine, or the skull base. thejns.org

5. Vital signs and weight.
   Look for clues of systemic effects, like changes related to repeated hypoglycemia (in Doege–Potter syndrome). PubMed

B) Manual tests

These are bedside maneuvers to understand mass effect. They are not specific for SFT, but they guide next steps.

6. Deep palpation and “compressibility” check.
   A very firm, non-compressible mass deep to fascia suggests a solid tumor.

7. Tinel’s sign over the mass.
   If tapping over a lump causes tingling down a limb, the mass may be compressing a nerve.

8. Range-of-motion testing of the nearest joint.
   Helps document functional impact if the mass limits motion.

9. Provocation of pain with stretch (e.g., gentle straight-leg raise for a pelvic mass pressing on the sciatic nerve).
   Again, not specific, but helps map nerve irritation.

10. Gentle Valsalva or cough impulse observation for neck or chest masses.
    A change in size or pressure sensation can hint at communication with thoracic spaces, guiding imaging choices.

C) Lab and Pathological tests

These tests confirm SFT and look for special features like IGF-2 excess.

11. Blood glucose during symptoms and basic metabolic panel.
    Low glucose with low insulin and low C-peptide suggests non-islet-cell tumor hypoglycemia from IGF-2, when present. PubMed

12. IGF-2 and IGF-1 levels (specialized).
    A high IGF-2 with low IGF-1 and a high IGF-2:IGF-1 ratio supports Doege–Potter syndrome. PMC

13. Core-needle biopsy (image-guided when deep).
    Small cylinders of tissue are taken for diagnosis. Pathologists examine standard H&E slides to look for the “patternless” or storiform pattern and the thin-walled branching vessels.

14. Immunohistochemistry (IHC).
    This is the key lab panel. STAT6 nuclear positivity is the hallmark. CD34 is often positive; BCL-2 and CD99 may be positive; S100 and desmin are usually negative. PMCNCBI

15. Molecular testing for NAB2–STAT6 fusion (RT-PCR/NGS) when needed.
    Confirms the genetic driver and can help in difficult cases or research. PMC

16. Mitotic count and Ki-67 index.
    Pathologists count mitoses per area and may stain for Ki-67 to estimate proliferation. These numbers feed into risk models. PubMed

17. Margins assessment after surgery.
    If the tumor is removed, the pathologist checks if edges are clear. Positive margins raise the risk of local recurrence. (General sarcoma principle; SFT data align with this approach.) NCBI

D) Electrodiagnostic tests

Not routine for every patient. Used when the tumor affects nerves or when episodes need clarification.

18. Nerve conduction studies / electromyography (EMG).
    If a limb mass causes numbness or weakness, EMG/NCS helps confirm nerve compression or injury.

19. Electrocardiogram (ECG) and continuous glucose monitoring during hypoglycemic spells.
    The ECG is to rule out hypoglycemia-related rhythm issues in severe cases; glucose monitoring documents frequency and depth of episodes until the tumor is treated in Doege–Potter syndrome. PubMed

E) Imaging tests

Imaging shows where the tumor is, how big it is, what it touches, and where it might have spread. Imaging patterns can suggest SFT but final proof needs tissue.

20. Ultrasound (for superficial or limb masses).
    Fast and helpful to see if a lump is solid and vascular.

21. Contrast-enhanced CT scan of the involved region.
    SFTs often appear well-circumscribed and hypervascular. Larger tumors may show lobulation and areas of necrosis. CT is also useful for chest disease and to check lungs for spread. MDPI

22. MRI with contrast of the primary site (especially limbs, pelvis, head/neck, or spine).
    MRI outlines the tumor’s relationship to muscle, fascia, nerves, vessels, and bone marrow. It helps surgeons plan a safe removal. SpringerOpen

23. CT chest for staging.
    Because lungs are a common site of spread, a dedicated chest CT is routine in staging. NCBI

24. PET-CT (FDG PET) in selected cases.
    Uptake varies in SFT, but PET can help survey the whole body for distant disease in higher-risk situations or unclear findings. SpringerOpen

25. Catheter angiography (less common today).
    Used when pre-operative embolization is planned for a very vascular tumor to reduce bleeding risk; also characterizes the tumor’s blood supply. SpringerOpen\

Non-pharmacological treatments (therapies & other measures)

Important: The gold-standard local therapy for SFT is complete surgical removal with negative margins whenever safely possible. Other measures support surgery, reduce recurrence risk, or improve quality of life.

1. Shared decision-making & tumor board review – Aligns surgery, radiation, and systemic options to your personal risk and site.

2. Surgical excision (definitive local therapy) – En-bloc resection with clear margins is the main curative step for localized disease. Early, complete surgery lowers local recurrence.

3. Prehabilitation – Targeted exercise, breathing practice, nutrition optimization before surgery improves recovery (guided by cancer nutrition/exercise guidance).

4. Preoperative arterial embolization – In selected highly vascular SFTs (orbit, skull base, pleura), embolization of tumor feeders can reduce blood loss and make resection safer; evidence is mainly case-series.

5. Adjuvant radiotherapy (after surgery) – Considered for positive/close margins or high-risk features to improve local control, especially in meningeal or head/neck sites; survival benefit is uncertain but local control may improve.

6. Definitive radiotherapy (if unresectable) – Used to shrink or control tumors when surgery isn’t feasible; responses vary.

7. Stereotactic radiosurgery/fractionated conformal RT – Focused options for intracranial SFT near critical structures.

8. Metastasectomy – Selected patients with limited lung or liver metastases can benefit from surgical removal to delay progression, individualized by a sarcoma team.

9. Symptom-guided pain care – Stepwise analgesia, nerve blocks when appropriate; aim is function with safety.

10. Nutritional therapy – Early dietitian support to maintain adequate protein and calories, prevent weight loss, and manage treatment side effects, per ESPEN cancer nutrition guidelines.

11. Safe hypoglycemia management education – For Doege-Potter, teach glucose monitoring, fast-acting carbohydrate use, and emergency plans while awaiting tumor-directed therapy.

12. Uncooked cornstarch at night (specialist-supervised) – Slow glucose release can blunt nocturnal hypoglycemia in NICTH while definitive therapy is arranged.

13. Physical therapy – Restores strength and mobility after surgery or radiation.

14. Pulmonary rehab / breathing exercises – Helpful for large intrathoracic SFTs or after thoracic surgery.

15. Psychosocial support & CBT – Reduces anxiety, improves coping.

16. Smoking cessation & alcohol moderation – Improves healing and treatment tolerance.

17. Vaccinations & infection prevention – Important if future systemic therapy may suppress immunity (flu shot, etc.).

18. Long-term surveillance plan – Scheduled imaging per risk model because late recurrences can occur years later; high-risk cases need closer follow-up.

19. Fertility counseling – If pelvic surgery or systemic therapy is planned.

20. Palliative care integration (when needed) – Maximizes quality of life alongside disease-directed care.

---

Drug treatments

Safety first: Doses below are typical adult regimens used in sarcoma practice or published studies; actual prescriptions are individualized by your oncologist based on age, organs, interactions, and goals. Evidence for SFT favors anti-angiogenic drugs (targeting VEGF/PDGFR pathways) over traditional chemotherapy in many advanced cases; responses still vary person-to-person.

1. Pazopanib (VEGFR/PDGFR TKI) – Class: multi-target TKI. Dose: 800 mg by mouth daily (continuous). Purpose: disease control in unresectable/metastatic SFT. Mechanism: blocks tumor blood-vessel signals. Side effects: high BP, liver enzyme elevation, fatigue, diarrhea, hand-foot syndrome. Evidence supports anti-angiogenic benefit in SFT.

2. Sunitinib (TKI) – Dose: 37.5 mg PO daily (continuous) or 50 mg 4 weeks on/2 weeks off. Purpose: second-line/selected first-line in advanced SFT. Mechanism: VEGFR/PDGFR inhibition. Side effects: fatigue, mucositis, cytopenias, hypertension. Retrospective series show activity.

3. Axitinib (TKI) – Dose: 5 mg PO twice daily, titrated. Mechanism/Purpose: anti-VEGFR; used after other TKIs. Side effects: hypertension, diarrhea, fatigue. Case series suggest benefit.

4. Sorafenib/Regorafenib (TKIs) – Dose: sorafenib 400 mg PO BID; regorafenib 160 mg PO daily, 3 weeks on/1 week off. Mechanism: anti-VEGFR/RAF (sorafenib) or multi-TKI (regorafenib). Side effects: hand-foot reaction, hypertension, fatigue. Reports of disease stabilization in SFT.

5. Temozolomide + Bevacizumab – Dose (one common regimen): temozolomide 150 mg/m² PO days 1-7 & 15-21 plus bevacizumab 5 mg/kg IV days 8 & 22, every 28 days. Purpose: metastatic/unresectable SFT (particularly hemangiopericytoma-spectrum). Mechanism: DNA alkylation + anti-VEGF antibody. Side effects: cytopenias, nausea (TMZ); hypertension/proteinuria (bevacizumab). Retrospective data show response/control.

6. Doxorubicin (± Ifosfamide) – Dose: doxorubicin ~75 mg/m² IV q3 weeks; ifosfamide dose varies. Purpose: standard sarcoma chemotherapy; in SFT responses are modest overall (better in dedifferentiated cases). Side effects: marrow suppression, cardiotoxicity (doxo), renal/CNS effects (ifos).

7. Dacarbazine (± Doxorubicin) – Dose: dacarbazine ~1,000 mg/m² IV q3 weeks (varies). Purpose: alternative cytotoxic option; sometimes combined with doxorubicin. Side effects: nausea, cytopenias. Clinical experience supports occasional responses.

8. Trabectedin – Dose: 1.5 mg/m² IV over 24 h q3 weeks (adjust for liver). Purpose: later-line STS therapy; case series report disease control in some SFTs. Side effects: liver enzyme elevation, fatigue, myelosuppression.

9. Eribulin – Dose: 1.4 mg/m² IV days 1 & 8 q21 days. Purpose: later-line; evidence in SFT is sparse (case reports). Side effects: neutropenia, fatigue.

10. Bevacizumab (alone) – Dose: 5–10 mg/kg IV q2–3 weeks. Purpose: anti-VEGF; sometimes used solo if TKIs aren’t tolerated. Side effects: hypertension, proteinuria, bleeding risk. Evidence mainly from small series.

---

Dietary “molecular” supplements

Important: No supplement has proven to cure SFT. Use these only to support nutrition and strength under professional guidance, following cancer-nutrition guidelines (ESPEN/ACS). Doses below are typical ranges for adults if your team agrees they fit your case.

1. High-protein oral nutrition supplement (e.g., whey/pea protein): Dose: enough to reach ~1.2–1.5 g protein/kg/day total intake. Function: maintain muscle and immunity. Mechanism: provides essential amino acids for repair.

2. Omega-3 (EPA/DHA): Dose: 1–2 g/day combined EPA+DHA (with food). Function: may help appetite and inflammation in cancer-related weight loss. Mechanism: modulates inflammatory cytokines and muscle metabolism. Evidence is mixed but reasonable.

3. Vitamin D (if deficient): Dose: per labs (often 1,000–2,000 IU/day; repletion protocols if very low). Function: bone/muscle health. Mechanism: nuclear receptor effects on muscle and immunity.

4. Multivitamin (RDA-level): Function: covers gaps if appetite is poor; avoid megadoses.

5. Creatine monohydrate: Dose: 3–5 g/day. Function: supports muscle performance during rehab. Mechanism: increases phosphocreatine stores.

6. Soluble fiber (psyllium, oats): Dose: 5–10 g/day. Function: bowel regularity; supports microbiome.

7. Probiotics (strain-specific): Function: may help antibiotic-associated diarrhea; discuss with team if neutropenic.

8. Branched-chain amino acids (BCAA): Dose: product-specific. Function: additional leucine to stimulate muscle protein synthesis.

9. Oral rehydration solution (electrolytes): Function: hydration if appetite low; supports BP and energy.

10. Uncooked cornstarch (only for Doege-Potter, clinician-supervised): Dose: individualized (e.g., 1–2 tbsp at bedtime). Function: slow glucose release for nocturnal hypoglycemia. Mechanism: extended starch digestion.

---

Regenerative / stem-cell-related” drugs

The idea of “hard immunity boosters” or “stem-cell drugs” does not match how SFT is treated. There are no approved stem-cell medicines for SFT. However, immunotherapy is being explored, mostly in case reports/early studies; some patients have responses. Below are oncology-grade immune approaches you might hear about. Always discuss risks/benefits and trial options with your sarcoma oncologist.

1. Pembrolizumab (PD-1 inhibitor) – Dose: 200 mg IV q3 weeks or 400 mg q6 weeks. Function: releases T-cell brakes to attack tumor. Mechanism: PD-1 blockade. Evidence: case reports of responses in SFT; overall benefit uncertain. Key risks: immune-related inflammation (thyroid, lung, colon, liver).

2. Nivolumab ± Ipilimumab (PD-1 ± CTLA-4 inhibitors) – Typical doses: nivolumab 240 mg q2 wks (or 480 mg q4 wks); ipilimumab 1 mg/kg q6–8 wks in combo regimens. Function/Mechanism: combined checkpoint blockade. Evidence: limited sarcoma-wide data; occasional SFT responses reported. Risks: higher immune-toxicity in combo.

3. Interferon-alpha (historical/rarely used today) – Function: anti-angiogenic and antiproliferative effects; case reports of stabilization in hemangiopericytoma-spectrum tumors. Risks: flu-like symptoms, mood changes.

4. Octreotide (select cases) – Function: somatostatin analog; occasionally used if tumors show somatostatin-receptor positivity, sometimes to help IGF-2 hypoglycemia control. Mechanism: hormone modulation. Evidence: case-based.

5. G-CSF/GM-CSF (supportive, not antitumor) – Help white-cell recovery during chemo; not “boosters” against SFT itself.

6. Clinical trials: dendritic-cell vaccines, adoptive T-cells, oncolytic viruses – Experimental; ask about trial availability at sarcoma centers.

---

Surgeries

1. Wide local excision / en-bloc resection – Remove the tumor with a rim of normal tissue for negative margins; main curative procedure in localized SFT.

2. Thoracotomy or VATS (for pleural/lung SFT) – Open or video-assisted approach to fully excise chest tumors while protecting lungs and vessels.

3. Skull-base or intracranial resection (often with neuronavigation) – For meningeal SFT; may be followed by radiotherapy depending on grade/margins.

4. Redo resection for local recurrence – Re-excision can restore local control when feasible.

5. Metastasectomy (e.g., lung nodules) – Selected patients benefit from removing limited metastatic deposits to prolong control.

---

Preventions

There is no proven way to prevent SFT from occurring, because the key driver is a spontaneous gene fusion. You can reduce complications and catch recurrences earlier:

1. Do not ignore a new or growing lump—seek evaluation.

2. Get expert pathology (STAT6 IHC) to avoid misdiagnosis.

3. Choose experienced sarcoma centers for surgery and follow-up.

4. Follow your individualized surveillance plan (imaging frequency guided by Demicco risk).

5. Keep vaccinations current (especially if systemic therapy is planned).

6. Stop smoking; limit alcohol—improves healing and treatment tolerance.

7. Maintain protein-adequate nutrition and physical activity to preserve strength.

8. Carry fast-acting carbohydrates if you have hypoglycemia episodes (per clinician plan).

9. Manage BP and lipids—important if you’ll take TKIs (they can raise BP).

10. Report new symptoms promptly (new cough, pain, neuro symptoms, weight loss, night sweats).

---

When to see a doctor right away

• You notice a new lump that is growing or feels deep/fixed.

• Persistent chest pain, cough, breathlessness—especially with a known chest lesion.

• Repeated low-sugar symptoms (sweats, tremors, confusion, fainting) or a measured low glucose.

• New neurologic symptoms (seizures, persistent headaches, weakness, vision/speech changes).

• After treatment: any new or worsening pain, unexplained weight loss, or symptoms that could mean recurrence.

---

What to eat and what to avoid

Goal: keep weight and strength stable through treatment and follow-up. Use individualized plans from a dietitian and your oncology team (ESPEN/ACS guidance).

What to eat :

1. Protein at every meal (fish, eggs, dairy/soy/legumes; add oral protein supplements if needed).

2. Whole-grain carbs for steady energy (brown rice, oats, whole-grain bread).

3. Colorful fruits and vegetables for fiber and micronutrients.

4. Healthy fats (olive oil, nuts, seeds; omega-3s can help appetite/inflammation).

5. Adequate fluids and electrolytes (water, oral rehydration solution during poor intake).

What to limit/avoid :

1. Alcohol (ACS: best to avoid, especially during treatment).
2. Ultra-processed foods and very sugary drinks (except as planned rescue for hypoglycemia in Doege-Potter).
3. Mega-dose supplements without medical advice (risk of interactions).
4. Grapefruit if you take TKIs (can alter drug levels—ask your pharmacist).
5. Raw/unsafe foods if you become neutropenic on chemo (food safety matters).

---

Frequently Asked Questions (FAQ)

1) Is SFT cancer?
SFT is a soft-tissue tumor that can be indolent or malignant. Even “conventional” SFT can sometimes recur or metastasize, so long-term follow-up is important.

2) What proves the diagnosis?
A core biopsy with nuclear STAT6 positivity on immunostaining is highly supportive; molecular testing often shows NAB2-STAT6 fusion.

3) What is the main treatment if it’s localized?
Complete surgical removal with clear margins is the cornerstone and is potentially curative.

4) Will I need radiation after surgery?
Sometimes. If margins are positive/close or the tumor has high-risk features, adjuvant radiotherapy may lower local recurrence risk (benefit varies by site).

5) What if the tumor cannot be fully removed?
Options include radiotherapy to control local disease and systemic therapy (often anti-angiogenic TKIs) to slow growth.

6) Which medicines work best for advanced SFT?
Evidence favors anti-angiogenic regimens (e.g., pazopanib, sunitinib, axitinib, temozolomide-bevacizumab), though responses vary. Classical chemo (e.g., doxorubicin) works in some, especially dedifferentiated tumors.

7) Is immunotherapy (e.g., pembrolizumab) helpful?
It can be—for some. There are case reports of responses, but data are limited; consider clinical trials where available.

8) What is my risk of the tumor coming back or spreading?
Your team uses the Demicco risk model (age, size, mitoses, necrosis) to estimate risk and tailor follow-up intensity.

9) How often will I need scans?
It depends on your risk category and site; higher-risk tumors get more frequent, longer-term imaging because late recurrences happen.

10) I keep having low blood sugar—what should I do?
Seek urgent care for severe symptoms. Treating the tumor usually fixes it. Meanwhile, glucocorticoids and nutritional measures like night cornstarch may help under specialist care.

11) Can SFT be inherited?
No—SFT is not known to be hereditary. The NAB2-STAT6 fusion happens in the tumor cells, not in all body cells.

12) Does diet cure SFT?
No. Nutrition supports strength and recovery but doesn’t replace surgery or oncology treatments. Follow ESPEN/ACS guidance for healthy intake.

13) Are there warning signs of recurrence?
New lumps, persistent pain, cough/breathlessness (chest), neurologic changes (CNS), or unexplained weight loss—all warrant evaluation.

14) Should I get treated only at a sarcoma center?
Whenever possible, yes—experienced teams improve diagnosis, surgery, and access to trials.

15) What’s the long-term outlook?
Outcomes vary widely. Low-risk tumors often do very well after complete resection. High-risk features call for closer monitoring and sometimes additional therapy.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 21, 2025.